Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children

Pediatric Critical Care Medicine

Volumn 10, Issue 3, 2009, Pages 323-327

  Creel, Amy M ^a   Durham, Spencer H ^b   Benner, Kim W ^c   Alten, Jeffrey A ^d   Winkler, Margaret K ^d  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sacred Heart Children's Hospital   (United States)

^c SAMFORD UNIVERSITY   (United States)

^d University of Alabama at Birmingham and Children's Hospital   (United States)

Author keywords

Methicillin resistant Staphylococcus aureus; Necrotizing pneumonia; Pediatric intensive care unit; Severe sepsis; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CLINDAMYCIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; DRUG TARGETING; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ANTIBIOTIC RESISTANCE; ISOLATION AND PURIFICATION; MEDICAL AUDIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; STATISTICS; UNITED STATES;

ADOLESCENT; ALABAMA; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS, PEDIATRIC; MALE; MEDICAL AUDIT; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 68849106597     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181988798     Document Type: Article

References (34)

1. Barrett FF, McGehee RF, Finland M: Methicillin-resistant Staphylococcus aureus at Boston City Hospital: Bacteriologic and epidemiologic observations. N Engl J Med 1968; 279:441-448
2. Daum RS: Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007; 357:380-390
3. Ochoa TJ, Mohr J, Wanger A, et al: Community-associated methicillin-resistant Staphylococcus aureus in pediatric patients. Emerg Infect Dis 2005; 11:966-968
4. Purcell K, Fergie J: Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: A 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005; 159:980-985
5. Al-Tawfiq JA, Aldaabil RA: Community-acquired MRSA bacteremic necrotizing pneumonia in a patient with scrotal ulceration. J Infect 2005; 51:c241-c243
6. Zetola N, Francis JS, Nuermberger EL, et al: Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005; 5:275-286
7. Klevens RM, Morrison MA, Nadle J, et al: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-1771
8. Pollack MM, Ruttimann UE, Getson PR: Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16:1110-1116
9. Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al: Severe Staphylococcus sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 2005; 115:642-648
10. Miles F, Voss L, Segedin E, et al: Review of Staphylococcus aureus infections requiring admission to a paediatric intensive care unit. Arch Dis Child 2005; 90:1274-1278
11. Castaldo ET, Yang EY: Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus: An emerging fatal problem. Am Surg 2007; 73: 684-687
12. Soriano A, Martinez JA, Mensa J, et al: Pathogenic significance of methicillin-resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30:368-373
13. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155
14. Lodise TP, McKinnon PS, Swiderski L, et al: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-1423
15. Micek ST: Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007; 45:S184-S190
16. Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42:S35-S39
17. Soriano A, Marco F, Martinez JA, et al: Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200 (Pubitemid 351269157)
18. Fowler VG Jr, Boucher HW, Corey GR, et al: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665
19. Moore MR, Perdreau-Remington F, Chambers HF: Vancomycin treatment failure associated with heterogeneous vancomycin-intermediance Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47:1262-1266
20. Wang G: Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-3886
21. Wollcott RD, Ehrlich GD: Biofilms and chronic infections. JAMA 2008; 299:2682-2684
22. Tenover FC, Moellering RC: The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-1215
23. Jeffres MN, Isakow W, Doherty JA, et al: Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: Specific evaluation of van-comycin pharmacokinetic indices. Chest 2006; 130:947-955
24. Khosrovanch A, Riederer K, Saeed S, et al: Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004; 38:1328-1330
25. Le J, Lieberman JM: Management of community-associated methicillin-resistant Staphylococcus aureus infections in children. Pharmacotherapy 2006; 26:1758-1770
26. Corne P, Marchandin H, Macia JC, et al: Treatment failure of methicillin-resistant SA endocarditis with linezolid. Scand J Infect Dis 2005; 37:946-949
27. Wunderink RG, Rello J, Cammarata SK, et al: Linezolid vs. vancomycin: Analysis of two double-blind studies of patients with MRSA nosocomial pneumonia. Chest 2003; 124: 1789-1797
28. Micek ST, Dunne M, Kollef MH: Pleuropul-monary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: Importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 367:73 1-739
29. Gomez J, Garcia-Vazquez E, Banos R, et al: Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: The role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007; 26:239-245
30. Frank AL, Marcinak JF, Margat PD, et al: Clin-damycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530-534
31. Siberry GK, Tekle T, Carroll K, et al: Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257-1260
32. American Academy of Pediatrics. Staphylo-coccal Infections. In: Red Book 2006 Report of the Committee on Infectious Diseases. Twenty-seventh Edition. Pickering LK, Baker CJ, Long SS (Eds). Elk Grove Village, IL, American Academy of Pediatrics, 2006, 603
33. Steenbergen JN, Alder J, Throne GM, et al: Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005; 55: 283-288 (Pubitemid 40425449)
34. Silverman JA, Mortin LI, Vanpraagh AD, et al: Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 2005; 191:2149-2152